Bethkis and Ceftazidime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Bethkis (tobramycin) and Ceftazidime (ceftazidime). Common drug interactions include weight decreased among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Bethkis and Ceftazidime. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Bethkis?

Bethkis has active ingredients of tobramycin. eHealthMe is studying from 2,409 Bethkis users. Check the latest studies of Bethkis.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

On Jul, 10, 2026

20 people who take Bethkis and Ceftazidime together, and have interactions are studied.

Bethkis and Ceftazidime drug interactions.

What are the common drug interactions of Bethkis and Ceftazidime, by gender? *:

female:

Weight decreased
Cystic fibrosis (disease of the secretary glands)
Hospitalisation
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Inflammation

male:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Acidosis (build-up of carbon dioxide in the blood)
Constipation
Cough
Cystic fibrosis (disease of the secretary glands)
Diarrhoea
Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)
Gastroenteritis norovirus (inflammation of stomach and intestine caused by norovirus infection)
Gastrointestinal disorder (functional problems of gastrointestinal tract)

What are the common drug interactions of Bethkis and Ceftazidime, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Cystic fibrosis (disease of the secretary glands)
Hospitalisation
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Inflammation

30-39:

Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Acidosis (build-up of carbon dioxide in the blood)
Constipation
Cough
Cystic fibrosis (disease of the secretary glands)
Diarrhoea
Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)
Gastroenteritis norovirus (inflammation of stomach and intestine caused by norovirus infection)
Gastrointestinal disorder (functional problems of gastrointestinal tract)

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 19 people, 95.00%
Wheezing (a high-pitched whistling sound made while you breath): 9 people, 45.00%
High Blood Pressure: 9 people, 45.00%
Asthma: 9 people, 45.00%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 9 people, 45.00%
Blood Glucose Decreased: 9 people, 45.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 9 people, 45.00%
Cough: 9 people, 45.00%
Sedation: 9 people, 45.00%
Fungal Infection: 9 people, 45.00%

* Approximation only. Some reports may have incomplete information.

Do you take Bethkis and Ceftazidime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously